# Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

> **NCT00545584** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1512 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** sitagliptin phosphate
- **BEHAVIORAL:** Comparator: Diet
- **BEHAVIORAL:** Comparator: Physical Activity

## Key facts

- **NCT ID:** NCT00545584
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-01
- **Primary completion:** 2009-11-19
- **Final completion:** 2009-11-19
- **Target enrollment:** 1512 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545584, "Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00545584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*